

Media Release

Zug, 20 May 2014

Ophthotech enters into licensing agreement with Novartis – share price rises more than 20% in after-market trading

Ophthotech Corporation (NASDAQ: OPHT), a listed company in the portfolio of HBM Healthcare Investments, announced yesterday after market that the Company has entered into a licence agreement with Novartis. Under the terms of the agreement, Ophthotech grants Novartis exclusive rights to commercialize Ophthotech's lead product candidate, Fovista™, in markets outside the United States. Ophthotech will receive an upfront payment of USD 200 million plus up to a further USD 830 million in contingent development, approval and sales milestones. In addition, Ophthotech will receive royalties on future ex-US sales of Fovista™. Ophthotech retains sole rights to commercialize Fovista™ in the United States. Please refer to Ophthotech's media release for further details.

HBM Healthcare Investments currently holds around 3.1 million shares in Ophthotech with a total value of USD 98.8 million based on the closing share price of USD 31.46 on 19 May 2014. The shares of Ophthotech rose more than 20% in the after-market trading.

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare
Investments

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmhealthcare.com
www.hbmhealthcare.com